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Abstract Background. Enzyme Replacement Therapy
(ERT) is the standard of care in Gaucher disease. The
effects of withdrawal or reduced doses are debated, thus a
retrospective cohort study was conducted to investigate
clinical and laboratory differences in 34 Gaucher type 1
patients experiencing an ERT dosage reduction after the
forced temporary imiglucerase shortage in 2009.
Methods. Haemoglobin concentration, leukocytes and
platelets counts, and chitotriosidase activity were assessed
at baseline and after 6 and 12 months (t0, t6, t12), while
bone pain, energy, work or school performance, concentra-
tion, memory and social life every 3 months.
Results. The cohort was made up of 18 males and 16
females (medians: age 41.8 years, therapy duration
14.1 years, dosage reduction 35.5%). Haemoglobin, leuko-
cytes and platelets remained substantially stable, while
chitotriosidase activity showed an increase, especially after t6.
Age, splenectomy or genotype were not associated with
laboratory parameters changes, except for a significant median
increase of chitotriosidase activity in non-splenectomised
patients after 12months (p ¼ 0.01). At 3, 6, 9 and 12 months,
more than 50% patients reported at least one problem in
subjective well-being (56%, 65%, 70%, 58%, respectively),
while bone pain occurred or worsened in 13/33, 13/32, 7/28
and 5/26 patients, respectively. No bone crises were reported.
Conclusions. Drug reduction did not induce substantial
modification in the laboratory values but seems to have
influenced the well-being perception of some Gaucher
patients. Thus, bone pain, general health and quality of life
should be carefully monitored during ERT reductions.
Background
Gaucher disease (GD), the most common lysosomal storage
disorder, is a recessive autosomal disease due tomutations in the
gene encoding the lysosomal enzyme acid beta glucosidase
(GBA1). The deficient activity of this enzyme results in the
accumulation of glucosylceramide (GlcCer) within the lyso-
somes. Type I (GD1) is the most common form of GD and
may imply a large variety of symptoms, ranging from
completely asymptomatic to child-onset forms (Beutler and
Grabowski 2001; Jmoudiak and Futerman 2005).
Several therapeutic approaches are being examined with
the aim to reduce the GlcCer intracellular burden, but Enzyme
Replacement Therapy (ERT) with human recombinant acid
beta glucosidase still remains the standard of care in these
patients (Hughes and Pastores 2010).
In June 2009, the European Medicines Agency (EMEA)
published a press release to communicate that after the viral
contamination (calicivirus of the type Vesivirus 2117) of
Genzyme’s manufacturing plant in Allston Landing (USA),
the company had to shut down the production of imiglu-
cerase (Cerezyme ®, Genzyme Corporation, MA, USA)
(EMEA 2009), causing the temporary worldwide shortage
of the drug.
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In 2009, imiglucerase was the only registered enzyme
available for ERT in GD (Hollak et al. 2010); consequently,
many patients under treatment were forced to withdraw or
reduce doses.
So far, several studies have been published to describe the
clinical consequences of this shortage (Giraldo et al. 2011;
Goldblatt et al. 2011; Zimran et al. 2011). Moreover, although
no trials were performed to ascertain the possible effects of a
temporary dosage reduction or withdrawal, this issue had
already been dealt with before the occurrence of imiglucerase
shortage (Drelichman et al. 2007; Elstein et al. 2000;
Grinzaid et al. 2002; Schwartz et al. 2001; Vom Dahl et al.
2001). However, each study analysed only a few patients and
the results among the studies were not homogeneous.
The aim of this study was to assess possible differences
in selected laboratory values and clinical aspects in patients
experiencing an ERT dosage reduction after the temporary
imiglucerase shortage in 2009.
Methods
A retrospective cohort study was conducted on a group of
GD1 patients. The inclusion criteria were having experi-
enced a drug reduction due to imiglucerase shortage in
2009 for at least 1 year and being followed up at the
Regional Coordinator Centre for Rare Diseases of the
University Hospital “Santa Maria della Misericordia”
(Udine, Italy) until July 2011.
The haemoglobin concentration (Hb) and white blood
cells (WBC) and platelets (Plt) counts were examined.
Chitotriosidase (Ct) activity, acknowledged as a marker of
disease (Hollak et al. 1994), was measured as previously
described (Hollak et al. 1994). These parameters were
evaluated no more than 6 months before the drug reduction
and after 6 and 12 months (t0, t6, t12, respectively). Since
a closer observation was performed after the shortage
(a phone call was made by the charge nurse every 3
months for 1 year), it was also possible to evaluate their
subjective condition after the drug dosage reduction. In
particular, patients were asked about the occurrence or the
worsening of bone pain. Several specific questions (five for
the adults and three for the paediatric patients) were also
asked about a decline in vitality/strength, work/school
performance, concentration/memory and social life after
the dosage decrease.
The Ethics Committee of the University Hospital “Santa
Maria della Misericordia” (Udine, Italy) approved this study.
Statistical Analysis
Continuous variables are described as median and first
and third quartile. Categorical variables are presented as
frequency and percentage. The Shapiro Wilk test was used
to check the normality assumption and since the variables
were not normally distributed, the signed rank test was used
to compare two groups. All the analyses were performed
using the statistical package Stata 11.0 (Stata Statistical
Software: Release 11.0, 2009. StataCorp LP, College
Station, TX, USA).
Results
Thirty-four out of the 38 Gaucher patients followed up until
July 2011 fulfilled the inclusion criteria and constituted the
study retrospective cohort. Eighteen patients were males
and 16 females, the median age was 41.8 years and 4 of
them were children (age < 16 years). Their main character-
istics are described in Table 1.
All patients were treated with imiglucerase when the drug
shortage occurred and all experienced one or two drug
reductions in July–August 2009. Their pre-reduction median
dosage was 55.5 units/kg/month, while the median dosage
after the decrease was 15.8 units/kg/month (signed rank test
p < 0.0001). The median percentage variation between the
pre- and post-reduction doses was 35.5% (Table 1).
Laboratory Values
Levels of Hb, WBC, Plt and Ct activity at baseline and at
6 and 12 months after drug reduction are summarised in
Table 1 Characteristics of the patients











Age, at therapy start (years) 27.8 (13.2–37.3)
Age, at reduction (years) 41.8 (29.2–50.5)




Before reduction 55.5 (48–63)
After reduction 15.8 (15–30)
% variation 35.5 (28–47)
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Table 2. Results of the comparisons t0-t6, t6-12, t0-t12
(signed rank test) are also reported.
Hb concentration did not show important variations
between t0 and t6 (median variation 0.1 g/dL, IQR
0.3  0.5, n ¼ 22), t6 and t12 (median 0.4 g/dL,
IQR 0.7  0.1, n ¼ 16) and t0-t12 (median 0.1, IQR
0.7  0.4, n ¼ 23). A decrease was evidenced in 7/22
patients at t6 and in 14/23 at t12, but none ever suffered
from anaemia, as defined by Pastores et al. (2004).
Overall, the WBC and platelets counts after 6 and
12 months were not statistically different from the baseline
values (Table 2). When compared to t0, WBC showed a
decrease in 8/22 patients at t6 and in 12/24 patients at t12,
while platelets were reduced at t6 in 10/22 patients and at
t12 in 13/22. However, only one reached a value lower than
100,000/mL (89,000 at t6).
When only the patients without missing values in the
measurements of Hb (n ¼ 16), WBC (n ¼ 17) and Plt
(n ¼ 16) were analysed separately, the results did not change.
Chitotriosidase activity significantly increased between
t6 and t12 (p ¼ 0.0004), with a median variation of
398 nmol/mL/h (IQR 55  590) in the 24 patients
examined, but did not vary between t0 and t6 (median
138, IQR 383  280, n ¼ 20) nor between t0 and t12
(median 311, IQR 49  634, n ¼ 21). Nevertheless,
when the patients without missing values were analysed
(n ¼ 20), Ct after 6 months (median 703; IQR 511–802)
was not different from Ct at t0 (median 555; IQR
334–940), but statistically significant increases were
noticed between t0 and t12 (median 1,114; IQR
516–1,391; p ¼ 0.04) and between t6 and t12 (p ¼ 0.01).
Comparisons were also made to assess whether being a
child, being splenectomised or having a particular genotype
(N370S/N370S vs N370S/other and other/other; N370S/
N370S and N370S/other vs other/other) might affect the
response to ERT shortage. No differences were found,
except when Ct activity at t0-t12 was compared between
splenectomised and non-splenectomised patients. While
splenectomised patients showed a non-significant median
decrease from 1,322 to 834 nmol/mL/h (p ¼ 0.17), the
non-splenectomised patients showed a significant median
increase from 543 to 1,191 nmol/mL/h (p ¼ 0.01).
Subjective Well-Being
Table 3 shows the number of patients who reported a
worsening in selected aspects of their life (energy, work or
school performance, concentration, memory, social life) at
different times after the drug reduction (3, 6, 9, 12 months).
More than 50% of patients declared at least one subjective
problem that arose 3, 6, 9 and 12 months after the drug
reduction (56%, 65%, 70%, 58%, respectively).
Figure 1 shows the distribution of the number of
problems that occurred after the drug reduction and
reported at the four different time points by the adult
patients who answered the five questions on subjective
Table 2 Laboratory values at t0, t6 and t12 and their differences between t0-t6, t6-12, t0-t12
Parameter (unit)
t0 t6 t12 t0-t6 t6-t12 t0-t12
Median (IQR) Median (IQR) Median (IQR) p-value p-value p-value
n n n n n n
Haemoglobin (g/dL) 14.0 (13.1–15.2) 14.6 (12.9–15.5) 14.1 (13.1–15.0) 0.28 0.02 0.20
n ¼ 30 n ¼ 22 n ¼ 25 n ¼ 22 n ¼ 16 n ¼ 23
White blood cells (n/mL) 5550 (4690–7255) 5460 (4780–7940) 6130 (5080–7790) 0.29 0.96 0.45
n ¼ 30 n ¼ 22 n ¼ 26 n ¼ 22 n ¼ 17 n ¼ 24
Platelets (103/mL) 193 (150–292) 198 (149–301) 231 (152–292) 0.75 0.78 0.97
n ¼ 30 n ¼ 22 n ¼ 24 n ¼ 22 n ¼ 16 n ¼ 22
Chitotriosidase (nmol/mL/h) 568 (349–919) 642 (467–787) 1,057 (543–1405) 0.88 0.0004 0.19
n ¼ 21 n ¼ 28 n ¼ 25 n ¼ 20 n ¼ 24 n ¼ 21
Chitotriosidase (nmol/mL/h)
(patients without missing values)
555 (334–940) 703 (511–802) 1,114 (516–1391) 0.88 0.04 0.01
n ¼ 20 n ¼ 20 n ¼ 20 n ¼ 20 n ¼ 20 n ¼ 20
Table 3 Problems that impaired the perception of well-being after
drug reduction, as reported by patients (compared to t0)
Problems t3 t6 t9 t12
#Energy 15/33 12/32 11/28 3/26
#Performance (work/school) 7/33 7/32 3/28 4/26
#Concentrationa 4/29 8/29 9/24 8/24
#Memorya 6/29 14/29 11/24 9/24
#Social lifea 4/28 5/28 3/25 2/24
"Tirednessb 1/4 1/3 1/3 0/2




well-being. As for children, at t3, one child out of four
reported one problem (tiredness), at t6 and t9, one child out
of three reported two problems (tiredness and loss of energy
in the same child), while at t12 none of the two children
reported problems.
Bone Pain
Thirty-three patients answered the questions about bone
pain; among these, 13 (2 children) already suffered from
bone pain before the drug reduction. The frequency of bone
pain onset in asymptomatic patients and its worsening in
patients already suffering from bone symptoms is reported
in Table 4. No patients suffered from bone crises.
Discussion
The aim of this study was to investigate whether the
imiglucerase dosage reduction due to the temporary shortage
in supplies had an effect on the clinical conditions and
laboratory parameters of 34 GD1 patients, four of whom
were children.
This is the only Italian study investigating the possible
consequences of this forced ERT dose reduction. Further-
more, even when considering the international literature,
only one previous study (Giraldo et al. 2011), focusing on
the effects of a dosage reduction rather than those of a
complete withdrawal, was performed. These authors
described a group of 17 Spanish GD patients and reported
stable values of Hb and Plt 6 months after ERT reduction,
consistently with the results of the present study. However,
a statistically significant increase of the chitotriosidase
activity was reported (p ¼ 0.03) after 6 months (Giraldo
et al. 2011), while the increase observed in the Italian
patients at the same time point did not reach statistical
significance but became significant between 6 and
12 months. The increase was even more evident when only
patients without missing values were taken into account,
since Ct increased from 555 at baseline to 703 at 6 months
and 1,114 at 12 months.





0 5 10 15 20 25 30
No. adult patients
no problems 1 problem 2 problems 3 problems 4 problems 5 problems
Fig. 1 Number of subjective problems reported by adult patients after the drug reduction. Note: only patients who answered all five questions
Table 4 Onset and worsening of bone pain after drug reduction
(compared to t0)
Bone pain t3 t6 t9 t12
Onset
Overall 5/20 6/19 4/18 4/17
Adults 5/18 6/17 4/16 4/15
Children 0/2 0/2 0/2 0/2
Worsening
Overall 8/13 7/13 3/10 1/9
Adults 8/11 6/12 2/9 1/9
Children 0/2 1/1 1/1 0/0
Onset or worsening
Overall 13/33 13/32 7/28 5/26
Adults 13/29 12/29 6/25 5/24
Children 0/4 1/3 1/3 0/2
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About 40 % (7/17) of the Spanish patients complained of
diffuse bone pain (Giraldo et al. 2011), consistent with the
fraction of patients of the present study that reported the
onset or worsening of bone pain at 3 and 6 months. While
no bone crises were observed in the Italian patients, Giraldo
et al. reported a bone crisis in three cases (Giraldo et al.
2011). This difference could be due to a different disease
severity in the two groups of patients, the Italian cohort
being milder.
As for ERT withdrawal, Elstein et al. reported stable
clinical conditions and laboratory values in 15 patients after
4 years of follow-up (Elstein et al. 2000), consistent with
the results of a Brazilian case report describing clinical
stability after a 3-month withdrawal (Schwartz et al. 2001).
However, several authors reported the deterioration of
haematological parameters (Hb, Plt, Ct) and an increase in
organomegaly (Zimran et al. 2011; Grinzaid et al. 2002;
Vom Dahl et al. 2001) after an ERTwithdrawal lasting from
3 to more than 24 months. Moreover, Giraldo et al. reported
conflicting results on 23 patients who withdrew ERT for
6 months, describing stable Hb and Plt in the great number
of patients but at the same time the occurrence of a bone
crisis in one patient and of mild anaemia in another one
(Giraldo et al. 2011). Two recent studies (Giraldo et al.
2011; Goldblatt 2011) showed that even if laboratory
parameters remained stable in most GD patients after
5–6 month of ERT withdrawal, some of them worsened
their clinical condition.
Therefore, it may be argued that some characteristics of
GD patients could play a role in the response to dosage
variation. Thus, in this study, the possible role of genotype,
age and splenectomy on the laboratory parameters after
ERT reduction was investigated. Among the four patients
described by Grinzaid et al., a better clinical and laboratory
behaviour was seen in the one with a N370S/N370S
genotype after a therapy discontinuation of 1 year
(Grinzaid 2002). On the contrary, among the Italian
patients, no differences were found in laboratory values
variations according to genotype.
No differences were even found when comparing
paediatric and adult patients, in contrast with a study
conducted in Argentina that reported a clear deterioration of
the clinical condition in five children forced to withdraw for
15–36 months (Drelichman et al. 2007).
Finally, the non-splenectomised patients showed a
significant increase in chitotriosidase activity between t0
and t12, while in splenectomised patients a non-significant
decrease was observed. This is in contrast with the study by
Czartoryska et al., reporting a more evident increase in
chitotriosidase activity after ERT cessation in two splenec-
tomised patients when compared to six non-splenectomised
patients (Czartoriska et al. 2000). However, the reduced Ct
activity in splenectomised patients could be explained with
the spleen removal itself, which leads to a reduction of the
number of macrophages and, in turn, to their Ct production.
In spite of the substantial maintenance of laboratory
values, more than one half of the studied patients reported
at least one problem that worsened their perception of well-
being during the follow-up period. Moreover, a variable
number of patients reported the onset or worsening of bone
pain (from about 40 % at t3 and t6 to about 20% at t12).
However, consideration of the psychological impact of
experiencing a forced reduction of a drug, that is thought to
be indispensable by the patient, cannot be underestimated.
In fact, the majority of these patients had good control of
GD under ERT treatment for years, being allowed to live
normal lives. When the shortage occurred, many patients
reported to be worried about a possible influence on the
outcome of their disease. Therefore, the subjective prob-
lems they reported could be influenced by this psychologi-
cal attitude. Finally, it is important to point out that the
information on both well-being and bone pain was not
gathered using a validated questionnaire and it is difficult to
evaluate the relevance of the problems reported.
Conclusions
In summary, the ERT dosage reduction did not cause
important changes in the laboratory parameters, except for
an increase of the Ct activity. Nevertheless, a part of GD
patients experienced some modification in their general
conditions. Therefore, when a decrease in ERT dosage
needs to be introduced, a careful evaluation of the general
health (with a special attention to bone pain) and quality of
life of each patient should be carried out.
Synopsis
Bone pain, general health and quality of life should be
carefully monitored during ERT reductions.
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